Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 4:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,410 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Hodgkin Lymphoma, Richter Transformation, Multiple Myeloma, T-cell-prolymphocytic Leukemia, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Myelofibrosis, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Neoplasm in Blast Phase
Interventions
LP-118
Drug
Lead sponsor
Newave Pharmaceutical Inc
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more
Conditions
Myeloid Leukemia
Interventions
Gilteritinib, Momelotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myeloid Leukemia, T Cell Acute Lymphoblastic Leukemia, T Cell Lymphoblastic Lymphoma
Interventions
XmAb18968 - Dose level 1, XmAb18968 - Dose level 0 (starting dose), XmAb18968 - Dose level 2, XmAb18968 - Dose level 3
Drug
Lead sponsor
Ehab L Atallah
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 3 more
Conditions
Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Lenalidomide
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Conditions
Acute Myeloid Leukemia
Interventions
A arm (DA-90), B arm (DAC), A arm (CLAG-M), B arm (FLAG-IDA)
Drug
Lead sponsor
Polish Adult Leukemia Group
Other
Eligibility
18 Years to 60 Years
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndrome, Mixed Phenotype Acute Leukemia
Interventions
Orca-T
Biological
Lead sponsor
Orca Biosystems, Inc.
Industry
Eligibility
Not listed
U.S. locations
8
States / cities
Los Angeles, California • Palo Alto, California • Tampa, Florida + 5 more
Conditions
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Polycythemia Vera, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
Azacitidine, Decitabine, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Sonidegib
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Leukemia
Interventions
aminopterin, leucovorin calcium
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
14
States / cities
Anaheim, California • Laguana Hills, California • Waterbury, Connecticut + 10 more
Conditions
Acute Myeloid Leukaemia
Interventions
S 64315 (also referred as MIK665) and venetoclax
Combination Product
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Houston, Texas
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
Infusion of NEXI-001 T Cells
Biological
Lead sponsor
NexImmune Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Duarte, California • Orlando, Florida • Detroit, Michigan + 2 more
Conditions
Acute Myeloid Leukemias
Interventions
Revumenib, Placebo, Intensive Chemotherapy Regimen
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
11
States / cities
Goodyear, Arizona • Duarte, California • Farmington, Connecticut + 8 more
Conditions
Cancer
Interventions
methotrexate, methylprednisolone, prednisone
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Enasidenib, Enasidenib Mesylate
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
24 Months to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 23 more
Conditions
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, CD45-Positive Neoplastic Cells Present, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts, Refractory Anemia With Ring Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
Interventions
Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Iodine I 131 Monoclonal Antibody BC8, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Tacrolimus, Total-Body Irradiation
Procedure · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
Hyperbaric oxygen
Drug
Lead sponsor
Omar Aljitawi
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Rochester, New York
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Acute Myeloid Leukemia
Interventions
ASTX727, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Conditions
Acute Myelogenous Leukemia
Interventions
Plerixafor, Clofarabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Interventions
laboratory biomarker analysis, quizartinib, sorafenib tosylate
Other · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Monrovia, California
Conditions
Acute Myeloid Leukemia
Interventions
SKI-G-801
Drug
Lead sponsor
Oscotec Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Whittier, California
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, busulfan, etoposide, fludarabine phosphate, prednisone, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation
Drug · Other · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
1 Year to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
Interventions
Thymoglobulin, Bortezomib, Tacrolimus
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Interventions
NC525
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Duarte, California • Miami, Florida • Boston, Massachusetts + 6 more